The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...
Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...
Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...
SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
Claims-based MarketScan analyses (>11,000 patients) showed moderate-to-severe alopecia areata carried higher atopic dermatitis risk than mild disease (adjusted HR 1.8; 95% CI 1.1–2.8). Baseline atopic ...
Severe alopecia areata is associated with elevated systemic inflammatory markers, which decrease with JAK inhibitor therapy, suggesting broader immune activation. The study identified higher levels of ...
The researchers found that patients perceived alopecia areata as chronic and life-impacting, with 81% reporting anxiety or depressive symptoms. HealthDay News — Alopecia areata (AA) has a severe ...
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is ...
The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results